June 28, 2016
CHICAGO, IL – June 28, 2016 — SAMDI Tech is expanding its executive leadership team as it announces Zachary A. Gurard-Levin as Chief Scientific Officer. Gurard-Levin was instrumental in the development of the SAMDI Technology during his graduate research with Dr. Milan Mrksich. Along with his extensive work in chromatin biology at the Institut Curie in Paris, he brings over 10 years of experience in Epigenetics and SAMDI Technology.
“I am thrilled to join SAMDI Tech to further expand its capabilities and client base. The increasing diversity in enzyme targets having therapeutic potential, including those beyond the epigenetics space, makes this a truly exciting time for SAMDI,” said Gurard-Levin.
“Zachary’s role in SAMDI Tech will be beneficial as we continue to evolve SAMDI Technology, and help clients in their drug discovery and drug development programs. His expertise in Epigenetics will bridge SAMDI Tech’s services and our clients’ needs to bring forth exceptional quality, enhanced scientific dialog, and timely data for decision making processes.” said Dr. Emilio Córdova, CEO of SAMDI Tech.
SAMDI is a unique label-free assay platform for measurement of complex biochemical activity.
Gurard-Levin holds a Bachelor’s Degree from John Hopkins University and Ph.D. in Chemistry from the University of Chicago.
About SAMDI Tech, Inc
SAMDI Tech, Inc, headquartered in Chicago, IL is a contract research organization supporting discovery research. SAMDI’s pioneering technology combines surface chemistry and MALDI mass spectrometry in both 384 and 1536 format for rapid assay development, high-throughput screening, and peptide substrate discovery and supports both biotech and large pharmaceutical companies. Learn more about SAMDI Tech at www.samditech.com.
For More Information:
SAMDI Tech, Inc.
Chief Executive Officer
Phone: +1 312 235 3575